Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)
نویسندگان
چکیده
منابع مشابه
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
OBJECTIVE This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas). RESEARCH DESIGN AND METHODS Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma gl...
متن کاملExenatide once weekly in type 2 diabetes.
The difficulties of maintaining long-term glycaemic control with available antidiabetic treatments in patients with type 2 diabetes have led to the need for additional treatments that can replace or be safely combined with existing agents. Patients with type 2 diabetes who have not achieved adequate glucose control at the maximum tolerated doses of their oral therapies have had no alternative o...
متن کاملInsulin degludec as an ultralong-acting basal insulin once a day: a systematic review
BACKGROUND Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations. OBJECTIVE The aim of this review is to assess the efficacy and safety data of IDeg in the treatment of t...
متن کاملDalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extreme...
متن کاملTolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care
INTRODUCTION Analyses of efficacy and tolerability of pharmacologic interventions are based on clinical trials that often include predominately white populations, in part because of challenges associated with recruitment and retention of racial/ethnically diverse study populations. Using real-world electronic health record (EHR) data, we sought to evaluate the tolerability and effectiveness of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Endocrine Society
سال: 2021
ISSN: 2472-1972
DOI: 10.1210/jendso/bvab048.903